Business Model

Calypso Biotech will develop its programs up to clinical proof-of-concept and will be looking for preferred pharmaceutical partners to take on further clinical development, manufacturing and commercialization.

We have chosen to develop fully human or humanized therapeutic antibodies, a reliable and well-established technology with numerous profitable marketed drugs and a low attrition rate.

The differentiation of Calypso Biotech products will come from their unique positioning as competitive (first-in-class/best-in-class profile) and proprietary compounds in niche indications, supported by an excellent translational medicine and biomarker package.